stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Net income
Palvella Therapeutics, Inc.'s net income for fiscal 2025 was −$41.7M, compared with −$17.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$61.7M. Over the past ten years it has ranged from −$45.7M (fiscal 2021) to $18.7M (fiscal 2023); the current reading is higher than 18% of that period. Palvella Therapeutics, Inc. ranks 352nd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$41.7M | — |
| FY2024 | −$17.4M | — |
| FY2023 | $18.7M | — |
| FY2022 | −$33.3M | — |
| FY2021 | −$45.7M | — |
| FY2020 | −$37.2M | — |
| FY2019 | −$25.5M | — |
| FY2018 | −$26.8M | — |
| FY2017 | −$17.6M | — |
| FY2016 | −$22.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$21.9M | — |
| Mar 2026 | −$15.8M | — |
| Dec 2025 | −$12.7M | — |
| Sep 2025 | −$11.3M | — |
| 41 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. | −$61.7M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on PVLA
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement